The frequent genetic and epigenetic changes in cancer cells present challenges and opportunities for treatment. On one hand, they contribute to drug resistance and treatment failure. On the other hand, understanding these changes can lead to the development of targeted therapies that specifically address the molecular abnormalities in cancer cells. For example, targeted therapies like tyrosine kinase inhibitors or monoclonal antibodies have been designed to target specific mutations or pathways involved in cancer.
